Empowered Funds LLC Purchases Shares of 16,680 Sage Therapeutics, Inc. (NASDAQ:SAGE)

Empowered Funds LLC purchased a new stake in Sage Therapeutics, Inc. (NASDAQ:SAGE) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 16,680 shares of the biopharmaceutical company’s stock, valued at approximately $91,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Inspire Investing LLC raised its holdings in shares of Sage Therapeutics by 30.4% in the 4th quarter. Inspire Investing LLC now owns 75,313 shares of the biopharmaceutical company’s stock valued at $409,000 after purchasing an additional 17,541 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Sage Therapeutics by 57.7% in the 4th quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 8,228 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Sage Therapeutics by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock valued at $8,975,000 after purchasing an additional 3,757 shares in the last quarter. State Street Corp raised its stake in Sage Therapeutics by 18.2% during the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock worth $21,127,000 after acquiring an additional 451,377 shares in the last quarter. Finally, RTW Investments LP raised its stake in Sage Therapeutics by 2.0% during the 3rd quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock worth $40,372,000 after acquiring an additional 111,123 shares in the last quarter. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on SAGE shares. Wedbush reiterated a “neutral” rating and set a $6.00 price target on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Oppenheimer cut their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Wednesday, October 30th. Stifel Nicolaus cut their price target on shares of Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating on the stock in a research note on Monday, December 16th. StockNews.com lowered shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Finally, Canaccord Genuity Group cut their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a research note on Wednesday, February 12th. Three equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $9.65.

Sage Therapeutics Trading Up 2.2 %

Shares of SAGE stock opened at $7.31 on Friday. The firm has a market capitalization of $449.42 million, a P/E ratio of -1.11 and a beta of 0.94. Sage Therapeutics, Inc. has a 1 year low of $4.62 and a 1 year high of $23.22. The firm’s fifty day simple moving average is $6.55 and its 200 day simple moving average is $6.80.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. Equities research analysts anticipate that Sage Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.